Confident Investing Starts With TipRanks Premium

Get 55% Off
TipRanks
Go Ultimate55% OFF

Carl Zeiss Meditec (AFXN) Stock Price & Analysis

AFXN Stock Chart & Stats

MX$1,350.00MX$0.00(0.00%)
At close:
No data to display
Day’s Range
MXN 1,350.00 - MXN 1,350.00
52-Week Range
MXN 1,350.00 - MXN 1,350.00
Previous Close
MXN 1,350.00
Volume
0
Average Volume (3M)
0
Market Cap
MXN 65.86B
Enterprise Value
MXN 2.72B
Total Cash (Recent Filing)
MXN 23.90M
Total Debt (Recent Filing)
MXN 0
Price to Earnings (P/E)
20.9
Beta
-0.10
Next Earnings
Dec 10, 2026 (Est.)
EPS Estimate
9.6
Next Dividend Ex-Date
N/A
Dividend Yield
2.26%

Bulls Say, Bears Say

Bulls Say

Balance Sheet Strength

Low leverage and a robust equity ratio provide Carl Zeiss Meditec with financial resilience over the next several quarters. This supports continued investment in medical technology, helps absorb operating pressure, and reduces the risk that debt obligations constrain strategic flexibility.

Cash Generation

Positive operating cash flow and a stable conversion of net income into cash indicate that reported earnings are supported by underlying business cash generation. This gives the company an internal source of funding for operations, service capabilities, and selective product investment.

Medical Technology Portfolio

Exposure to ophthalmic diagnostics, surgical systems, and microsurgery creates a broad medical technology portfolio rather than reliance on one procedure or device category. Installed systems can also support services, upgrades, software, and consumables, reinforcing customer continuity.

Bears Say

Margin Pressure

Declining net profit, EBIT, and EBITDA margins indicate that strong gross profitability is not fully translating into operating and bottom-line earnings. If sustained, this pressure could reduce reinvestment capacity and make future growth less efficient over the coming quarters.

Weaker Free Cash Flow

A decline in free cash flow growth and weaker free-cash-flow conversion can limit the cash available for innovation, acquisitions, shareholder returns, or balance-sheet strengthening. Persistent deterioration would make expansion more dependent on operating improvement or external funding.

Earnings And Revenue Decline

The reported contraction in revenue and sharp EPS decline point to weaker current operating momentum than the company’s longer-term growth profile suggests. Continued pressure would make it harder to leverage the installed base and could prolong the margin recovery required.

Carl Zeiss Meditec News

AFXN FAQ

What was Carl Zeiss Meditec’s price range in the past 12 months?
Carl Zeiss Meditec lowest stock price was Mex$1350.00 and its highest was Mex$1350.00 in the past 12 months.
What is Carl Zeiss Meditec’s market cap?
Carl Zeiss Meditec’s market cap is Mex$65.86B.
When is Carl Zeiss Meditec’s upcoming earnings report date?
Carl Zeiss Meditec’s next earnings report is estimated for Dec 10, 2026 (not yet confirmed), which is in 38 days.
How were Carl Zeiss Meditec’s earnings last quarter?
Carl Zeiss Meditec released its earnings results on Aug 06, 2026. The company reported Mex$11.368 earnings per share for the quarter, beating the consensus estimate of Mex$8.631 by Mex$2.737.
Is Carl Zeiss Meditec overvalued?
According to Wall Street analysts Carl Zeiss Meditec’s price is currently Overvalued.
Does Carl Zeiss Meditec pay dividends?
Carl Zeiss Meditec does not currently pay dividends.
What is Carl Zeiss Meditec’s EPS estimate?
Carl Zeiss Meditec’s EPS estimate is 9.60.
How many shares outstanding does Carl Zeiss Meditec have?
Carl Zeiss Meditec has 89,440,570 shares outstanding.
What happened to Carl Zeiss Meditec’s price movement after its last earnings report?
Carl Zeiss Meditec reported an EPS of Mex$11.368 in its last earnings report, beating expectations of Mex$8.631. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Carl Zeiss Meditec?
Currently, no hedge funds are holding shares in MX:AFXN
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology